Google
BIAF Stock Analysis — BIOAFFINITY TECHNOLOGIES, INC. (Healthcare >> Diagnostics & Research)
BIAF FAQ
What is BIAF's ROE?
BIOAFFINITY TECHNOLOGIES, INC. reports a Return on Equity (ROE) of -433.71%.
What is BIAF's dividend yield?
BIOAFFINITY TECHNOLOGIES, INC. offers a dividend yield of 0.00%.
What is BIAF's Quality Score?
Our AI rates BIAF's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy BIAF?
Our AI Timing Score for BIAF is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does BIAF belong to?
BIOAFFINITY TECHNOLOGIES, INC. is classified under the Healthcare >> Diagnostics & Research sector on the NASDAQ exchange
BIAF AI Analysis Summary
Our AI summary for BIAF: BIOAFFINITY TECHNOLOGIES, INC. (NASDAQ), Healthcare >> Diagnostics & Research sector. The stock currently trades at a P/E of 0.00, ROE of -433.71%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.63
Price
-0.02
(-2.64%)
Day Change
|
|
|---|
BIAF, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.63 |
| PBV / Sector |
1.11 / -29.69
GREAT
|
| Earning Per Share | -2.46 |
| PE / Sector |
N/A / 48.18
|
| PEG or PE/Growth / Sector |
N/A / 1.64
|
| Average 1M Daily Value |
0.29 M
GREAT
|
| Average 1W Daily Value |
0.18 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
47% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 07:59:33 |
| Symbol | BIAF |
| Name | BIOAFFINITY TECHNOLOGIES, INC. |
| Sector | Healthcare >> Diagnostics & Research |
| Market | NASDAQ |
| Listed Shares | 6.28 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 4.05 / 38,081.42 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 3300 Nacogdoches Road, San Antonio, TX, United States, 78217
Phone: 210 698 5334
Website: https://bioaffinitytech.com
Employees: 57
Description: bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Diagnostics & Research
Click a bubble to view stock details · Bubble size represents market capitalization share
